An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Status: RECRUITING

Eligibility Criteria

Age: 16 years to 80 years old

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

* Participants aged ≥18 and ≤80 years of age at Screening. Where permitted locally, participants 16 to \<18 years of age who meet the definition of Tanner Stage 5 for development * Confirmed diagnosis of moderately to severely active Crohn's Disease (CD) for at least 3 months prior to baseline * Demonstrated inadequate response, have shown loss of response or intolerance to conventional therapies or advanced therapies (ATs)

Exclusion Criteria:

* Participants with Ulcerative Colitis (UC) or indeterminate colitis * Participants with two entire missing segments of the: terminal ileum, right colon transverse colon, sigmoid and left colon, and rectum * Prior or current high-grade gastrointestinal (GI) dysplasia * Participants on treatment with but not on stable doses of conventional therapy prior to baseline * Participants receiving prohibited medications or therapies * Participants with previous exposure to anti-TL1A investigational therapy The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Conditions & Interventions

Interventions:
DRUG: Duvakitug, DRUG: Placebo
Conditions:
Crohn's Disease

More Information

Contact(s): Trial Transparency email recommended (Toll free for US & Canada) - Contact-US@sanofi.com
Principal Investigator:
IRB
Number:
System ID: NCT07184931

Thank you for choosing StudyFinder. Please visit http://studyfinder.cctr.vcu.edu to find a Study which is right for you and contact ctrrecruit@vcu.edu if you have questions or need assistance.